Novartis Pharmaceuticals
This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments
Sjogren's Syndrome
Ianalumab
Phase 2
This is an open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome.}}
Study Type : | Interventional |
Estimated Enrollment : | 21 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ianalumab in Patients With Sjögren's Syndrome |
Actual Study Start Date : | July 27, 2022 |
Estimated Primary Completion Date : | June 26, 2026 |
Estimated Study Completion Date : | June 28, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment Arm Ianalumab 300 mg subcutaneous monthly |
Biological: Ianalumab |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Novartis Investigative Site
Brest, France, 29200